Actively Recruiting
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Led by Chinese University of Hong Kong · Updated on 2026-02-24
110
Participants Needed
1
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated. Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.
CONDITIONS
Official Title
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chinese ethnicity
- Age between 55 and 80 years old
- Age-Related White Matter Change Scale score of 2 or early 3 on FLAIR MRI
- Modified Functional Ambulation Classification of 5 or higher
- Montreal Cognitive Assessment score below 25
- Both diabetic and non-diabetic patients are eligible
- Ability to understand the study and provide informed consent
You will not qualify if you...
- Diagnosed dementia or MoCA score lower than the 2nd percentile for age and education
- Cerebral white matter changes caused by other diseases such as CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, or multiple sclerosis
- Contraindications to GLP-1R agonist including thyroid carcinoma, pancreatic issues, proliferative retinopathy, hypersensitivity to GLP-1R agonist, or family history of multiple endocrine neoplasia
- Body mass index less than 18.5 kg/m2
- Contraindications to imaging such as advanced kidney disease, acute kidney injury, gadolinium contrast allergy, or non-MRI safe implants
- Medical conditions preventing adherence to the protocol or completion of the study
- Established neurodegenerative disorders like Parkinson's or Alzheimer's Disease
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
P
Pauline Kwan, Master
CONTACT
H
Hung Trista, Bachelor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here